Malignant liver tumours include a wide range of primary and secondary tumours. Although
surgery remains the mainstay of curative treatment, modern therapies integrate a variety of …

The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …

Colorectal cancer (CRC) is the third most common cancer worldwide, with 1.1 million new
cases per year, and is the second leading cause of cancer death. 1 CRC occurs more …

PURPOSE To develop recommendations for treatment of patients with metastatic colorectal
cancer (mCRC). METHODS ASCO convened an Expert Panel to conduct a systematic …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background The triplet FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus
bevacizumab showed improved outcomes for patients with metastatic colorectal cancer …

Colorectal cancer is a prevalent disease worldwide, with more than 50% of patients
developing metastases to the liver. Despite advances in improving resectability, most …

Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients …

Simple Summary Colorectal cancer (CRC) is the third most common cancer worldwide.
Metastasis to secondary organs, such as the liver and lungs, is a key driver of CRC-related …